Phreesia, Inc. (NYSE:PHR – Get Free Report) SVP David Linetsky sold 11,685 shares of Phreesia stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $27.48, for a total transaction of $321,103.80. Following the completion of the sale, the senior vice president now owns 231,271 shares in the company, valued at approximately $6,355,327.08. This trade represents a 4.81 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
David Linetsky also recently made the following trade(s):
- On Wednesday, December 18th, David Linetsky sold 24 shares of Phreesia stock. The stock was sold at an average price of $25.38, for a total transaction of $609.12.
- On Monday, December 16th, David Linetsky sold 35 shares of Phreesia stock. The shares were sold at an average price of $24.88, for a total value of $870.80.
- On Wednesday, December 11th, David Linetsky sold 11,853 shares of Phreesia stock. The stock was sold at an average price of $24.85, for a total value of $294,547.05.
Phreesia Stock Up 1.1 %
PHR stock opened at $29.03 on Friday. Phreesia, Inc. has a fifty-two week low of $17.07 and a fifty-two week high of $29.90. The company’s 50 day moving average price is $24.78 and its 200 day moving average price is $23.24. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74. The firm has a market capitalization of $1.69 billion, a price-to-earnings ratio of -19.75 and a beta of 0.94.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on PHR shares. Needham & Company LLC restated a “buy” rating and set a $29.00 price target on shares of Phreesia in a report on Friday, January 10th. Citigroup raised their target price on Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, January 10th. KeyCorp increased their price target on Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Wednesday, January 8th. Royal Bank of Canada upgraded shares of Phreesia from a “sector perform” rating to an “outperform” rating and boosted their price objective for the company from $24.00 to $32.00 in a report on Wednesday, January 8th. Finally, Robert W. Baird lowered their target price on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Thirteen analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $31.15.
Read Our Latest Analysis on PHR
Institutional Trading of Phreesia
Institutional investors have recently bought and sold shares of the business. Versor Investments LP purchased a new position in shares of Phreesia in the 3rd quarter valued at about $694,000. Zacks Investment Management purchased a new position in Phreesia in the third quarter valued at approximately $631,000. Sei Investments Co. raised its holdings in Phreesia by 135.3% during the second quarter. Sei Investments Co. now owns 165,327 shares of the company’s stock worth $3,505,000 after purchasing an additional 95,058 shares in the last quarter. State Street Corp lifted its position in shares of Phreesia by 7.1% during the 3rd quarter. State Street Corp now owns 1,327,586 shares of the company’s stock worth $30,256,000 after buying an additional 88,517 shares during the last quarter. Finally, Wesbanco Bank Inc. boosted its holdings in shares of Phreesia by 76.9% in the 4th quarter. Wesbanco Bank Inc. now owns 46,000 shares of the company’s stock valued at $1,157,000 after buying an additional 20,000 shares in the last quarter. 92.10% of the stock is owned by hedge funds and other institutional investors.
Phreesia Company Profile
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
Read More
- Five stocks we like better than Phreesia
- High Dividend REITs: Are They an Ideal Way to Diversify?
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Why Are Stock Sectors Important to Successful Investing?
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- 3 Ways To Invest In Coffee, Other Than Drinking It
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.